Pharmaceutical

Tavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion Therapeutics

Agreement includes the discovery and enhancement of targeted oncology drug targets and biomarkers, in addition to positioning existing compoundsDURHAM, N.C.,…

5 months ago

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members…

5 months ago

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage…

5 months ago

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in…

5 months ago

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024

PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage…

5 months ago

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

Call Scheduled for Today, Tuesday, May 14, 2024 at 5:00 pm ETLITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos…

5 months ago

Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an…

5 months ago

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of…

5 months ago

MiNK Reports First Quarter 2024 Results

Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American…

5 months ago

Alimera Sciences Reports First Quarter 2024 Results

Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024…

5 months ago